Real-Life Effect of a Microcrystalline Tyrosine Adjuvanted Mite Immunotherapy in Patients with Allergic Rhinitis

Abstract

<b>Aim:</b> Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus^® in a 1-year prospective multicentered real-life study. <b>Methods:</b> A total of 118 adults with allergic rhinitis sensitized to <i>Dermatophagoides</i> received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolution of the combined symptom and medication score. Secondary end points included other effectiveness outcomes and measurement of product tolerability. <b>Results:</b> Acarovac Plus induced significant improvements in primary and secondary end points after 6 months compared with baseline. These differences persisted after 1 year of treatment (p < 0.001; baseline vs 1 year): combined symptom and medication score (1.60 vs 0.79). No serious adverse events were recorded. <b>Conclusion:</b> Acarovac Plus for 1 year was effective and well tolerated in a real-life setting.